BTCRC- LUN18-153: A Randomized Phase II Trial of Adjuvant Pembrolizumab versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) with Primary Tumors between 1-4 cm

BTCRC- LUN18-153: A Randomized Phase II Trial of Adjuvant Pembrolizumab versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) with Primary Tumors between 1-4 cm

The following study has recently been activated for patient enrollment by The University of Illinois Cancer Center Clinical Trials Office (CTO). Clink on the link to learn about the details regarding the study on clinicaltrials.gov.

For more information or questions about a study, email cancertrials@uic.edu or call 312-355-5112.

BTCRC- LUN18-153: A Randomized Phase II Trial of Adjuvant Pembrolizumab versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) with Primary Tumors between 1-4 cm

Sponsor: Greg Durm, MD, Big Ten Cancer Research Consortium

Principal Investigator: Lawrence Feldman, MD

Leave a Reply